Abstract
Colon cancer is a leading cause of cancer related mortality. Until very recently the only existing options that medical oncologists had to treat metastatic colon cancer were a combination of chemotherapy, anti-EGFR and anti-angiogenic agents. We currently have the first proof that immune therapies could be an effective approach to battle colorectal cancers that carry a mismatch repair machinery deficient phenotype. It is expected that as our knowledge of the different mechanisms of immune-resistance grows, this therapeutic modality might soon be applicable to all patients. However, due to the continuous increase in the cost of oncological drugs, some treatment overheads may soon become prohibitive for many. In this review we will examine the current evidence related to this topic with the objective to provide the reader with concise but practical information about the potential role of immunotherapy in CRC.
Keywords: Colon cancer, lynch syndrome, microsatellite instability, PD-1 blockage, pembrolizumab.
Reviews on Recent Clinical Trials
Title:What is the Current Role of Immunotherapy for Colon Cancer?
Volume: 11 Issue: 2
Author(s): Fernando Galanternik, Gonzalo Recondo, Matías E. Valsecchi, Martín Greco, Gonzalo Recondo, Máximo de la Vega and E. Diaz Cantón
Affiliation:
Keywords: Colon cancer, lynch syndrome, microsatellite instability, PD-1 blockage, pembrolizumab.
Abstract: Colon cancer is a leading cause of cancer related mortality. Until very recently the only existing options that medical oncologists had to treat metastatic colon cancer were a combination of chemotherapy, anti-EGFR and anti-angiogenic agents. We currently have the first proof that immune therapies could be an effective approach to battle colorectal cancers that carry a mismatch repair machinery deficient phenotype. It is expected that as our knowledge of the different mechanisms of immune-resistance grows, this therapeutic modality might soon be applicable to all patients. However, due to the continuous increase in the cost of oncological drugs, some treatment overheads may soon become prohibitive for many. In this review we will examine the current evidence related to this topic with the objective to provide the reader with concise but practical information about the potential role of immunotherapy in CRC.
Export Options
About this article
Cite this article as:
Galanternik Fernando, Recondo Gonzalo, E. Valsecchi Matías, Greco Martín, Recondo Gonzalo, de la Vega Máximo and Diaz Cantón E., What is the Current Role of Immunotherapy for Colon Cancer?, Reviews on Recent Clinical Trials 2016; 11 (2) . https://dx.doi.org/10.2174/1574887111666160330121851
DOI https://dx.doi.org/10.2174/1574887111666160330121851 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer
Current Medicinal Chemistry Nanoparticle Based Delivery of Protease Inhibitors to Cancer Cells
Current Medicinal Chemistry Unravelling the Role of Infectious Agents in the Pathogenesis of Human Autoimmunity: The Hypothesis of the Retroviral Involvement Revisited
Current Molecular Medicine Cellular FLICE-Like Inhibitory Protein (C-FLIP): A Novel Target for Cancer Therapy
Current Cancer Drug Targets Guaraná a Caffeine-Rich Food Increases Oxaliplatin Sensitivity of Colorectal HT-29 Cells by Apoptosis Pathway Modulation
Anti-Cancer Agents in Medicinal Chemistry L-Arginine Modulates Glucose and Lipid Metabolism in Obesity and Diabetes
Current Protein & Peptide Science Development of Novel Therapeutic Drugs in Humans from Plant Antimicrobial Peptides
Current Protein & Peptide Science Modelling DNA Repair Pathways: Recent Advances and Future Directions
Current Pharmaceutical Design Editorial [Hot Topic: Targeted Therapies for Pancreatic Cancer Executive (Guest Editor: Qingyong Ma)]
Current Pharmaceutical Design High-Risk HPV/ErbB-2 Interaction on E-Cadherin/Catenin Regulation in Human Carcinogenesis
Current Pharmaceutical Design Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets Embryonic Stem Cell MicroRNAs: Defining Factors in Induced Pluripotent (iPS) and Cancer (CSC) Stem Cells?
Current Stem Cell Research & Therapy Exosomes Harnessed as Nanocarriers for Cancer Therapy - Current Status and Potential for Future Clinical Applications
Current Molecular Medicine Tyrosine Kinase Update: Role and Response in Cancer Therapy
Current Cancer Therapy Reviews Proteinases as Biomarkers in Breast Cancer Prognosis and Diagnosis
Mini-Reviews in Medicinal Chemistry Camptothecin: Therapeutic Potential and Biotechnology
Current Pharmaceutical Biotechnology HR MAS MR Spectroscopy in Metabolic Characterization of Cancer
Current Topics in Medicinal Chemistry Translational Research and Standardization in Optical Imaging
Current Molecular Imaging (Discontinued) FOXM1-Dependent Transcriptional Regulation of EZH2 Induces Proliferation and Progression in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry The Interaction of GLUT1 and FOXM1 Leads to a Poor Prognosis in Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry